Contract Manufacturing, Biopharmaceutical Production

A CDMO’s Perspective on Outsourcing Challenges for ADCs–Part 2

February 12, 2025

Christian Morello, vice president and head of the Bioconjugates Business Unit at Lonza, looks at what is involved in developing modern ADCs.

A CDMO’s Perspective on Outsourcing Challenges for ADCs–Part 1

February 11, 2025

Christian Morello, vice president and head of the Bioconjugates Business Unit at Lonza, discusses the challenges and unmet needs in bringing ADCs to market.

Advancing ADCs to the Next Level

February 04, 2025

CDMOs who have integrated technologies can help further the advancement of ADC development.

Samsung Biologics Scores Major Manufacturing Deal Worth Over $1.4 Billion with European Pharma Company

January 17, 2025

Production is set to take place at Samsung Biologics’ Songdo, South Korea, site, and the agreement will run through December 2030, subject to change.

Scinai Immunotherapeutics Establishes US CDMO Business Unit

December 19, 2024

Scinai Bioservices Inc. has been established in Delaware as the company's new US-based subsidiary, which will serve biotech companies in early stage drug development.

Leveraging Advancements in Bioanalytical Testing

December 05, 2024

As the field of bioanalytical testing evolves, it is important for drug developers to stay at the forefront of the advancements to ensure they remain competitive.

Fujifilm's Cell Therapy Facility Expansion Completed

November 23, 2024

The Thousand Oaks, Calif., cell therapy manufacturing facility now houses new production suites, updated development labs, and more after expansion.

CDMO SEKISUI Expands its CGMP Biopharma Manufacturing Capacity

November 20, 2024

SEKISUI has used a £15.7 million (US$20.7 million) investment to expand its clinical-grade drug substance manufacturing at its UK site.

Ascend Advanced Therapies Expands US Footprint in New Partnership

November 12, 2024

Ascend is partnering with EW Healthcare Partners to expand capabilities in the United States.

CMOs and Hybrid Companies Predicted to Hold 54% of Biologics Capacity in 2028, According to CPHI Annual Survey

October 08, 2024

According to the annual survey, four of the five biggest biologics capacity holders in 2028 will comprise CMOs, which are expected to have 45% of all CMO capacity in Asia.